BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright ©The Author(s) 2025.
World J Cardiol. Nov 26, 2025; 17(11): 110178
Published online Nov 26, 2025. doi: 10.4330/wjc.v17.i11.110178
Table 1 Baseline characteristics of the study population stratified by prehospital aspirin use, n (%)
Variable
Aspirin (n = 90)
No aspirin (n = 233)
P value
Age (year), mean ± SD74.2 ± 14.366.9 ± 16.7< 0.001
Male sex49 (54.4)113 (48.5)0.338
BMI (kg/m²), mean ± SD29.7 ± 7.429.7 ± 7.20.986
Hypertension58 (64.4)125 (53.6)0.079
Coronary artery disease44 (48.9)21 (9.0)< 0.001
Chronic kidney disease15 (16.7)23 (9.9)0.089
Active malignancy18 (20.0)59 (25.3)0.314
Smoking history47 (52.2)109 (46.8)0.380
Heart rate on admission (bpm)89.0 ± 19.394.6 ± 21.40.032
Table 2 Comparison of clinical outcomes between aspirin and non-aspirin groups
Outcome
Aspirin (n = 90)
No aspirin (n = 233)
P value
OR (95%CI)
ICU admission16.7%28.8%0.0250.496 (0.266-0.924)
Shock2.2%9.9%0.0210.208 (0.048-0.899)
RV strain (CT)22.2%34.8%0.0290.536 (0.305-0.944)
In-hospital mortality3.3%11.6%0.0220.260 (0.080-0.889)
Mechanical ventilation6.7%4.7%0.4831.442 (0.517-4.021)
EKOS therapy3.3%11.2%0.0470.275 (0.081-0.931)
Cardiac arrest6.7%6.0%0.8261.117 (0.416-3.004)
Table 3 Clinical outcomes associated with prehospital aspirin use, n (%)
Outcome
Aspirin (n = 90)
No aspirin (n = 233)
P value
OR (95%CI)
RV strain on CT20 (22.2)81 (34.8)0.0290.54 (0.31-0.94)
RV strain on echocardiogram12 (13.3)36 (18.9)0.2460.66 (0.32-1.34)
ICU admission15 (16.7)67 (28.8)0.0250.50 (0.27-0.92)
Pressor requirement2 (2.2)23 (9.9)0.0210.21 (0.04-0.90)
In-hospital mortality3 (3.3)27 (11.6)0.0220.260 (0.080-0.889)
EKOS therapy3 (3.3)26 (11.2)0.0470.28 (0.08-0.93)
Mechanical ventilation6 (6.7)11 (4.7)0.4831.44 (0.52-4.02)
Cardiac arrest6 (6.7)14 (6.0)0.8261.12 (0.42-3.00)